



Ref: ADL/SE/2025-26/71

February 5, 2026

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

Dear Sir/Madam,

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Ref: Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Newspaper Publication of Financial Results

In accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith newspaper publication of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2025, published in the following newspapers on Thursday, February 5, 2026:

- 1) Financial Express (English)
- 2) Pratahkal (Marathi)

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932



Published in Financial Express (English) on Thursday i.e. February 5, 2026



Aarti Drugs Limited

Registered Office: Plot No. N-198, MIDC, Tarapur, Village Pamtembhi, Dist. Palghar - 401 506, Maharashtra
CIN: L37060MH1984PLC055433 Email ID: investorrelations@aartidrugs.com Website: www.aartidrugs.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

PARTICULARS	Standalone						Consolidated					
	Quarter Ended		Period Ended		Year Ended		Quarter Ended		Period Ended		Year Ended	
	31.12.2025 (Audited)	30.09.2025 (Audited)	31.12.2024 (Audited)	31.12.2025 (Audited)	31.12.2024 (Audited)	31.03.2025 (Audited)	31.12.2025 (Audited)	30.09.2025 (Audited)	31.12.2024 (Audited)	31.12.2024 (Audited)	31.12.2024 (Audited)	31.03.2025 (Audited)
Total Income	53,002	57,910	52,591	163,047	156,256	218,723	60,294	65,288	56,850	184,664	172,476	240,339
Net profit for the period (before tax, exceptional and/or extraordinary items)	2,171	5,578	5,203	12,274	12,808	19,875	2,902	6,041	5,076	14,054	14,062	21,177
Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
Net profit for the period after Tax (after exceptional and/or extraordinary items)	3,384	4,178	3,853	12,426	9,583	15,731	4,055	4,516	3,709	13,968	10,533	16,810
Other Comprehensive Income (after tax)	-	-	-	-	-	113	31	-	(46)	43	31	159
Total Comprehensive Income for the period	3,384	4,178	3,853	12,426	9,583	15,844	4,086	4,516	3,663	14,011	10,563	16,969
Weighted average number of equity shares used for computing earnings per share (face value of Rs. 10/- each)	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127	9,127
Earnings per share (in Rs.) (not annualised)												
(a) Basic	3.71	4.58	4.22	13.61	10.50	17.18	4.44	4.95	4.06	15.30	11.54	18.35
(b) Diluted	3.71	4.58	4.22	13.61	10.50	17.18	4.44	4.95	4.06	15.30	11.54	18.35

Notes:

- 1) The above results for the Quarter & Period ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd February, 2026.
- 2) The Board of Directors have declared Interim Dividend of Rs.2.00/- (Rupee Two) per Equity Share of Rs. 10/- each (20%) amounting to Rs. 18,25,40,000 for the Period ended 31st December, 2025.
- 3) As on December 31, 2025 the Company has 3 (three) subsidiaries, namely, Pinnacle Life Sciences Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA.
- 4) The company has completed the buyback of 6,65,000 equity shares of face value of Rs. 10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors' fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.) ("Buyback Size") on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs. 10/- each.
- 5) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment has also published draft Central Rules and FAQs on aforesaid labour codes. The detailed impact assessment is currently in progress, necessary adjustments, if any, will be identified and appropriately accounted for in Q4 FY2025-26.
- 6) Company has only one business segment i.e. pharmaceuticals.
- 7) The Company's new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025.
- 8) Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- 9) The aforesaid Audited Financial Results are uploaded on the Company's website www.aartidrugs.com and also available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. The same data can be accessed by scanning the QR code provided below:



For Aarti Drugs Limited

Sd/-

Prakash M. Patil

Chairman, Managing Director & CEO

DIN: 00005618

Place: Mumbai

Date: 3rd February, 2026

Published in Pratahkal (Marathi) on Thursday i.e. February 5, 2026

प्रातःकाल
www. pratahkal. COM

ਮੁੰਬਈ, ਗੁਰੂਵਾਰ ਦਿ. ੫ ਫੇਵ੍ਰੁਵਾਰੀ ੨੦੨੬ ੫

आरती डूग्ज लिमिटेड

नॉटिविकृत कार्यालय : खून्ड खांगा एन-१९६, एमआरडीसी, तारापु, गाव पामतेगां, जि. पातलर - ४०१ ५०६, महाराष्ट्र
 सीआयएन : L37060MH1984PLC055433 ईमेल आयडी : investorrelations@aartidrugs.com वेबसाइट : www.aartidrugs.com

३१ डिसेंबर २०२५ रोजी संपलेल्या तिमाहीसाठी लेखापरीक्षित आर्थिक निकालांचे विवरण

ठिकाण: मुंबई^१
तारीख: ३ फेब्रुवारी २०२६

आरती इंडिया लिमिटेडसाठी

सहा/-

प्रकाशन एम. पाटोल
अस्याक्ष, व्यवस्थापकीय संचालक आणि सीईओ
डीआयएन: ०२००५६५८